Thomas Lenz participated in the The IPA World Congress + Probiota 2025, the leading Microbiome industry event 5 – 7 February, in Copenhagen. It was dynamic sessions, stimulating roundtable lunch discussions, information about the latest insights from the industry and interesting meetings and networking.
fredrik
A collaboration Agreement with a chinese partner was signed for introducing AgeViva as a antiaging food supplement product in China. The work with the inlicensing in China have already started after the signing of the contract January 13.
A new production of our patented yeast is being produced by Jästbolaget ahead of the launch of our patented anti-aging product AgeViva™ in Q1 2025.
Our trademark AgeViva™ was approved Nov 29.
Trevor Archer, Thomas Lenz and Roger Karlsson visited Sapienza University Nov 25-28. The team at Sapienza with professor Rita Businaro presented new results in antiaging studies. The presentation showed new very positive and strong study results for the important hallmarks of longevity/antiaging: autophagy, anti-inflammageing and anti-oxidative stress
Trevor Archer and Thomas Lenz, has participated in the 30th annual which took place this year in Stockholm November 4-6. BIO-Europé is one of the top pharma events in Europe. The BIO-Europe program explores the impact of the Swedish approach, embodied by an openness to collaboration, has had on biotech innovation, and addresses the latest trends, challenges and opportunities in life science. Milmed received a lot of positive interest in its new patented longevity/antiaging product.… Read More »30th annual BIO-Europe
Milmed Unico’s new subsidiary Longevience AB is registred the 11th of October. Everything related to longevity and antiaging will be in our new company.
The 18th of June Milmed Unico AB submitted a new patent application, ”YEAST FOR PROMOTING LONGEVITY AND/OR ANTIAGING”. We believe that there are good conditions now to get this application approved, because the patent have very strong scientic results from our antiaging studies. There is both in vivo and in vitro studies performed at Sapienza university showing clear and positive effects on six main hallmarks for longevity and antiaging. This patent application is very important… Read More »New patent application submitted
Trevor Archer and Thomas Lenz participated in the 6th Biotech-Hanse Forum At the event, Trevor presented our latest research conducted at Sapienza University. The Biotech Hanse Forum assembles key players and emerging companies from the Swedish and German (language region) Pharma and Biotech Industry and provides a unique opportunity to present to a selected audience.
The future of Microbiome-based Medicinal Products Milmed Unico AB’s CEO, Thomas Lenz, has participated in the Pharmabiotics Conference in Lyon 21-22 March 2023: “The Future of Microbiome-based Medicinal Products”. Pharmabiotic Research Institute (PRI) | European Microbiome Regulatory Science Center hosted the 8th annual 2023 Pharmabiotics Conference in Lyon, France. The conference bring in scientific and industry presentations which touch on nearly every aspect of a microbiome-based health product’s path to market, from fundamental and discovery/pre-clinical… Read More »Pharmabiotics Conference in Lyon 21-22 March 2023